The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder https://sabrinawajn276077.blogitright.com/40486811/high-investor-pharma-the-speculative-investment